The aim of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.

Start Date05 Jul 2023

Sponsor / Collaborator

GI Alliance Holdings LLC

[+3]

NCT05571735

/ RecruitingNot ApplicableIIT

Immunogenicity of COVID-19 Vaccines Against Coronavirus Disease (COVID-19) Among Tuberculosis (TB) Patients in Thailand-Myanmar Border.

This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54).
Each participant will receive single or double doses of one of COVID-19 vaccines (Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine or Janssen Ad26.COV2.S COVID-19 vaccine) in the deltoid muscle of the non-dominant arm. Study Duration approximately 1 year. The main focus of this study is to compare the humoral and cellular immunological responses of the COVID-19 vaccines between bacteriologically confirmed TB patients under treatment vs healthy individuals.
This study is funded by the Wellcome Trust. The grant reference number is 220211/A/20/Z.

Start Date15 Apr 2023

Sponsor / Collaborator

University of Oxford

100 Clinical Results associated with COVID-19 Vaccine(Janssen)

100 Translational Medicine associated with COVID-19 Vaccine(Janssen)

100 Patents (Medical) associated with COVID-19 Vaccine(Janssen)

13,389

Literatures (Medical) associated with COVID-19 Vaccine(Janssen)

31 Dec 2026·Expert Review of Vaccines

Approaches to observational study designs and analytical options to evaluate the safety of multi-dose vaccines: a systematic review

Review

Author: Douglas, Ian J. ; Hien Trang, Tu Pham ; Mtei, Monica ; Schultze, Anna ; Navarro-Torné, Adoración

INTRODUCTION:

Observational studies require careful considerations when evaluating the safety of multidose vaccines. We reviewed design and analytical approaches in observational studies evaluating the safety of multidose vaccines in the post-licensure phase.

METHODS:

EMBASE, MEDLINE, Web of Science, and Scopus (2018-2022) were searched for hypothesis-testing studies evaluating the safety of multidose vaccines. Key features from frequently used designs were extracted.

RESULTS:

Among 123 eligible studies, cohort (46%) and self-controlled case series (SCCS)/self-controlled risk interval (SCRI) (40%) followed by case-control (12%) were the most common designs, and 15% of studies used multiple designs. Among cohort studies evaluating multiple doses, vaccination date (36%) and cohort entry with time-updated exposure status (32%) were frequent approaches used to define time zero. Twenty-eight percent of cohort studies did not report time zero; all but one evaluated COVID-19 vaccine effect on post-delivery and fertility-related outcomes. For SCCS/SCRI, 64% of studies accounted for event-dependent exposures, mainly by including pre-exposure periods (53%) and modified SCCS model (48%), while 20% employed multiple correction strategies. Among studies using multiple designs, 68% reached consistent conclusions.

CONCLUSIONS:

SCCS/SCRI and cohort designs dominate multidose vaccine safety studies. Clear reporting on time zero in pregnancy and fertility-related cohort studies, and on addressing event-dependent exposures in SCCS/SCRI studies is needed, along with guidance on interpreting results from multiple designs.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021–23

Article

Author: Hanson, Kayla E. ; McNeil, Michael M. ; Duffy, Jonathan ; DeSilva, Malini B. ; Jackson, Lisa A. ; Sundaram, Maria E. ; Daley, Matthew F. ; Irving, Stephanie A. ; Kieke, Burney A. ; Belongia, Edward A. ; Boyce, Thomas G. ; McClure, David L. ; Hurley, Laura P.

Vaccine-associated enhanced disease (VAED) was recognized as a theoretical risk when COVID-19 vaccines were authorized. Epidemiologic data can identify a signal for VAED if vaccine effectiveness (VE) is negative for preventing serious illness. In 2021, we initiated a cohort study to examine VAED indirectly by estimating VE against COVID-19 hospitalization and severe illness in the Vaccine Safety Datalink. The study cohort included VSD enrollees who were age-eligible to receive mRNA COVID-19 vaccine from February 2021-March 2023. Outcomes were initial COVID-19-associated hospital admission and severe in-hospital complications (acute respiratory distress or failure). VE was estimated by dose, variant period, and for early (14-119 d) and late (≥120 d) post-vaccination periods. VE was defined as 100*(1- adjusted hazard ratio). Relative VE (rVE) was estimated for bivalent vaccine versus ≥2 monovalent vaccine doses. The hospitalization analysis included all 16,027 enrollees with COVID-19 hospitalization and a 5% random sample of non-hospitalized enrollees who contributed person-time (n = 138,238). Two-dose original monovalent VE against hospitalization exceeded 90% in most age groups during the pre-Delta and Delta periods. VE was lower during the Omicron period. During the Omicron BA.2/BA.4/BA.5/XBB period, a fourth monovalent dose or bivalent dose generated VE of 59%-78% across age groups with modest waning. rVE was 48%-60% across age groups for bivalent vaccine vs. ≥2 original monovalent doses. Overall, the results were similar for VE against severe in-hospital complication. In conclusion, there was no signal for VAED during any variant period or for any specific dose of monovalent or bivalent vaccine.

31 Dec 2026·Human Vaccines & Immunotherapeutics

NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

Article

Author: Young, Barnaby E. ; Poh, Xuan Ying ; Sadarangani, Sapna P. ; Yeoh, Aileen Y. Y. ; Chavatte, Jean-Marc ; Rao, Suma ; Lim, Daniel R. X. ; Chia, Po Ying ; Tang, Hao Ling ; Wang, Lin-Fa ; Tan, Chee Wah ; Chin, Yi-Qing ; Rahman, Nabilah ; Tan, Cheryl C. Y. ; Gandhi, Mihir ; Renia, Laurent ; Ng, Lisa F. P. ; Lye, David C. ; Mah, Shirley Y. Y. ; Lin, Raymond T. P.

Randomized clinical trials comparing the breadth and long-term persistence of immunity between different COVID-19 vaccine types and between ancestral and Omicron-targeted vaccines are limited. The PRIBIVAC study (Phase D) is a randomized clinical trial comparing the immunogenicity of monovalent mRNA vs bivalent mRNA vs protein-based NVX-CoV2373 administered as second booster in 176 triple mRNA-vaccinated adults. Primary objective was neutralizing antibody levels against Omicron subvariants at day 28. A 4th vaccine dose significantly boosted 50% neutralization titers against emerging strain XBB.1.16 by 3.2-, 4.1- and 1.6-fold in monovalent mRNA, bivalent mRNA and NVX-CoV2373 group respectively at day 28. The largest absolute increase in inhibition level at day 28 post-booster was observed against the KP.2 subvariant, with bivalent mRNA vaccines exhibiting the highest neutralization level (91.7%) compared with monovalent mRNA (84.4%; p = .027) and NVX-CoV2373 (81.4%; p < .0001). While bivalent mRNA vaccines elicited the highest early immunogenicity, neutralization levels against all Omicron variants tested waned to similar levels between groups by 12 months post-vaccination. Although NVX-CoV2373 induced a lower peak anti-S antibody response, anti-S decay rate was slower in NVX-CoV2373 compared with mRNA vaccines. The geometric mean anti-S fold change (D360/D28) in NVX-CoV2373 group was higher (0.51) relative to both mRNA vaccines (monovalent: 0.31, p = .010 and bivalent: 0.35, p = .017). Improved neutralizing antibody responses against diverse SARS-CoV-2 variants by the ancestral or variant vaccine highlight the immunological benefits of COVID-19 vaccine boosters regardless of the latest variant-based vaccine. Further studies to determine if different vaccine combinations translate to differing protection against infection remain necessary.

1,246

News (Medical) associated with COVID-19 Vaccine(Janssen)

11 Aug 2026

·healthcare-digital.com

The Race to Develop a Bundibugyo Ebola Virus Vaccine

Both vaccine candidates leverage the same technology used to develop the COVID-19 vaccine. Credit: Unsplash Amid a growing outbreak, Oxford University researchers and Moderna announced that clinical trials for a Bundibugyo virus strain vaccine have begun In close succession, two separate candidates for an Ebola vaccine to tackle the deadly Bundibugyo strain have entered Phase 1 clinical trials. It provides a ray of hope amid an Ebola outbreak in the DR Congo (DRC) which, according to DRC public health estimates, has seen a recorded 3,973 cases and 1,801 deaths recorded as of 4 August 2026. Oxford University researchers are behind one of the trials, while Moderna is advancing the other in Canada, with both leveraging technology used to develop the COVID-19 vaccine. In addition, a clinical trial of a potential post-exposure prophylaxis medicine is underway, led by the DRC’s National Institute for Biomedical Research, supported by an international consortium of research and outbreak-response partners. Key statistics behind the current Ebola outbreak 3,973 cases and 1,801 deaths have been recorded as of 4 August 2026. Cases are rising faster than the 2014–2016 West Africa epidemic, which remains the largest Ebola outbreak on record. Treatment infrastructure is improving, with a 100-bed treatment centre opening in Bunia, capital of Ituri province - the epicentre of the outbreak. Moderna leads the pharma industry’s efforts Moderna announced clinical trials began on 4 August 2026. The vaccine candidate draws on Moderna's mRNA platform — the same technology that proved capable of rapid development, scalability and worldwide rollout during the COVID-19 pandemic. It also builds on work Moderna has already put into filoviruses, the family of viruses that includes Ebola. Stéphane Bancel, CEO of Moderna. Credit: LinkedIn "Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no approved vaccine currently exists," says Stéphane Bancel, Chief Executive Officer of Moderna. The programme sits within Moderna's partnership with the Coalition for Epidemic Preparedness (CEPI), which has pledged up to US$50m toward preclinical work and the Phase 1 trial. "We are grateful to CEPI, Health Canada, the investigators and study participants for their contributions to advance this work," continues Stéphane. That funding also covers scaling up manufacturing of trial doses alongside early-stage clinical work, a move designed to enable larger Phase 2 and Phase 3 trials to launch quickly should the Phase 1 data hold up. "Getting Moderna's vaccine candidate into a Phase 1 trial this rapidly is a major step forward in the fight against this deadly outbreak," says Dr. Richard Hatchett, CEO of CEPI. Getting Moderna's vaccine candidate into a Phase 1 trial this rapidly is a major step forward in the fight against this deadly outbreak Dr. Richard Hatchett, CEO of the Coalition for Epidemic Preparedness. Using the COVID vaccine template On 13 July 2026, Oxford University announced that researchers were initiating the first clinical trials for the Bundibugyo strain. The trial will test the safety of the ChAdOx1 BDBV vaccine and the immune response it triggers in 50 healthy adults between 18 and 55. Volunteer recruitment has begun, and the first recruits have received doses of the vaccine candidate. To get the study up and running quickly and push the vaccine candidate into clinical testing, the Serum Institute of India (SII) has manufactured and stockpiled roughly 620,000 doses. Scientists at the University of Oxford's Oxford Vaccine Group and Pandemic Sciences Institute developed the vaccine candidate using the same viral vector platform behind the Oxford/AstraZeneca COVID-19 vaccine – a vaccine credited with saving over six million lives in its first year alone. Professor Katrina Pollock, MRC Clinician Scientist in Vaccinology and Chief Investigator at the Oxford Vaccine Group. Credit: University of Oxford Professor Katrina Pollock, MRC Clinician Scientist in Vaccinology and Chief Investigator at the Oxford Vaccine Group, says: 'Launching this first-in-human study of a Bundibugyo ebolavirus vaccine is an important milestone for the programme and the culmination of a significant effort by teams across vaccine development, manufacturing and clinical testing. “We are focused on delivering a rigorous Phase 1 trial, to the highest standard of care, to evaluate the safety, tolerability and immune responses generated by the vaccine.” A race against time As both vaccine candidates move through the clinical trial process, the search for a safe, effective vaccine candidate is a pressing race against time. The current outbreak is the second-largest in history, only behind the 2014-2016 West African epidemic, which claimed 11,325 lives and infected over 28,600 people. With concerns among health officials that the virus could be mutating, the vital work by Moderna and Oxford University researchers is of paramount importance in protecting global health. Dr. Richard Hatchett, CEO of CEPI. Credit: World Bank "This fast-growing epidemic is already the second-largest Ebola outbreak in history, and cases are rising more quickly than they did in the 2014 - 2016 West Africa epidemic, which remains the largest on record. "Every day matters, and every vaccine candidate in clinical trials gives us another shot at getting a safe, effective vaccine to the people who need it as swiftly as possible," says Richard. Company portals Moderna Executives Stéphane Bancel Founding CEO

29 Jul 2026

·www.pharmaindustrial-india.com

EU Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine

Pfizer and BioNTech SE announced that the European Commission (EC) has granted marketing authorisation for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season. The ETF stated that “the evidence suggests that targeting XFG would provide the best protection against COVID-19.” The marketing authorisation is valid in all 27 European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway. Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine at risk to ensure supply readiness in anticipation of the respiratory disease season, when the demand for COVID-19 vaccination is expected to increase. EU Member States as well as Norway, will be supplied either via the EC contract or according to individual country government policies. The EC approval follows the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation from July 23, 2026 based on the cumulative body of evidence previously submitted by Pfizer and BioNTech that includes clinical, non-clinical and real-world data supporting the safety and efficacy of the Pfizer and BioNTech COVID-19 vaccine as well as manufacturing/quality and non-clinical data showing that the monovalent XFG-adapted COVID-19 vaccine generated strong immune responses against currently circulating SARS-CoV-2 lineages, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 and other contemporary lineages. The companies have also submitted data for the updated COVID-19 vaccine to regulatory authorities around the world. The companies are continuing to monitor the evolving epidemiology of COVID-19 in preparation to meet global public health needs. The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the marketing authorisation holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the US, the EU, the UK, and other countries, and the holder of emergency use authorisations or equivalents in other countries.

28 Jul 2026

·www.prnewswire.com

American Lung Association Highlights Therapeutic Options Available to Prevent and Treat COVID-19

Campaign aims to advance lung health through healthcare provider education focused on available options to help people at high risk for severe illness CHICAGO, July 28, 2026 /PRNewswire/ -- Respiratory viruses remain a leading cause of morbidity and mortality in the U.S., with COVID-19 continuing to pose a significant health burden. There have been incredible advancements in COVID-19 prevention and treatment, so the American Lung Association launched a new campaign today to help individuals who deliver care understand the current COVID-19 therapeutic options available for their eligible adult patients to help prevent severe disease. The U.S. Centers for Disease Control and Prevention (CDC) estimates that from October 1, 2025 through May 2, 2026, there have been 3.8-12.3 million illnesses, up to 250,000 hospitalizations, and 41,000 deaths due to COVID-19. "COVID-19 is still a persistent public health issue in the U.S. COVID-19 is highly transmissible, so preventing disease is particularly important for people at high risk of severe illness and complications from the infection," said Harold Wimmer, President and CEO for the American Lung Association. "Thankfully, there have been significant advancements in both preventing and treating COVID-19, but unfortunately, these are underutilized. Healthcare providers are the most trusted source of health information, so it is critical for them to be up to date on the options available, and to discuss these options with their patients." COVID-19 prevention and proven-effective treatments are underutilized. In fact, antiviral use remains under 15%, and only 16% of eligible patients receive treatment within 5 days of infection. According to the CDC, only 18% of adults and 9% of children received the COVID-19 vaccine in the 2025-26 respiratory virus season. Only 31% of adults 65-74 and 37% of adults 75+ received a COVID-19 vaccination. Available Options for Preventing COVID-19 COVID-19 vaccination is the most effective way to prevent severe illness and hospitalization over prolonged periods of time, but other prevention strategies include: Post-exposure prophylaxis with ensitrelvir, an oral antiviral medication, for use in people 12 years of age and older following contact with an individual who has COVID-19 (medication to help prevent severe COVID-19 illness after contact with someone sick with COVID-19). Pre-exposure prophylaxis with pemivibart, an antibody delivered through an IV, for use in people who are moderately or severely immunocompromised (medication to help prevent severe COVID-19 illness before exposure to someone who has COVID-19). Individual prevention actions, including: Take steps for cleaner air, particularly when there is someone sick in the house, out in crowded places or when hosting a gathering; Practice good hand hygiene; Prompt testing and treatment for individuals at increased risk; and Wearing a mask to help lower the risk of COVID-19 transmission. Available Options for Treating COVID-19 Treatment options are available for individuals at increased risk who test positive for COVID-19 to help prevent severe illness, lessen the duration of illness and reduce the risk of hospitalization. Depending on a person's situation, healthcare providers may prescribe one of these treatments: Oral antiviral medications or IV infusion antiviral medication which may reduce the replication of the virus within the body. These medications should be taken as soon as possible after symptoms appear – oral antivirals no later than five days and IV infusion no later than seven days after symptom onset. Many individuals are at high risk for severe illness if they get sick with COVID-19. Those at high risk include people aged 65 and older, people with chronic lung disease (including asthma, COPD, interstitial lung disease, cystic fibrosis or pulmonary hypertension), those who used to or currently smoke, and adults with certain medical conditions, including those who are immunocompromised, and those with heart disease, diabetes and chronic kidney disease. Survey data continues to show that healthcare providers are the most trusted sources of health information, so it is important for them to recommend COVID-19 vaccination and discuss additional options to prevent serious illness for their patients at increased risk. Receipt of a 2024-25 COVID-19 vaccine dose provided additional protection against COVID-19-associated emergency department/urgent care visits and hospitalization among adults. Individuals are encouraged to talk with their healthcare provider to see if they are eligible for updated COVID-19 vaccines along with any other vaccinations recommended for them. Supporting healthcare providers with up-to-date resources about COVID-19 therapeutic options is critical to improving health outcomes, particularly as emerging therapies evolve and become available, so the American Lung Association, with support from Shionogi, is working to: Deliver clear, evidence-based COVID-19 education to healthcare providers, including specialists such as pulmonologists, regarding available antiviral options for their patient population. Reinforce the importance of COVID-19 treatment and prevention options for eligible adults, including those at increased risk for severe illness. Support provider awareness of available COVID-19 therapies through targeted outreach. For more information, visit Lung.org/hcp-covid. About the American Lung Association The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and a Platinum-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org. Jill Dale | American Lung Association P: 312-940-7001 M: 720-438-8289E: [email protected] SOURCE American Lung Association 21% more press release views with Request a Demo

Vaccine

100 Deals associated with COVID-19 Vaccine(Janssen)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07B	DB15857

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
COVID-19	United States	Janssen Pharmaceuticals, Inc.	27 Feb 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05515042 (Pubmed \| Lancet HIV)	Phase 2	COVID-19	694	BNT162b2 (people with HIV)	zcrmhbrqcw(auzflbljtp) = qzkmnwpwhb qamlkhvkuy (hwmcqkiggy, 8.6 - 11.7)	Positive	01 Mar 2026
NCT04998240 (Pubmed \| Clin Infect Dis)	Phase 4	COVID-19	367	BBIBP-CorVAd26.COV2.S + BBIBP-CorVAd26.COV2.S	azocoomlpu(lgokmnhhib) = tbgrvpsoce ynelidejmo (mrslzcqhrr, 635.3 - 1014.3)	Non-inferior	22 Jul 2025
				BBIBP-CorV	azocoomlpu(lgokmnhhib) = aipflmsltd ynelidejmo (mrslzcqhrr, 150.8 - 272.1)
NCT04765384 (HORIZON 1, CTgov)	Phase 2	COVID-19	51	messenger Ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine+COVID-19 mRNA vaccine (Group 1 (Adults): Ad26.COV2.S 5*10^10 vp)	gabswhgouc = hvrxwxsesg szrgmtwtai (lnzmthmifl, udospsvghb - iqufhzkewj) View more	-	13 Nov 2024
				Ad26.COV2.S (Groups 2 and 3 (Adults): Ad26.COV2.S 5*10^10 vp)	gabswhgouc = iamairswji szrgmtwtai (lnzmthmifl, hhxyuejueh - pqseetzdqp) View more
NCT04614948 (ENSEMBLE2 \| ENSEMBLE 2, CTgov)	Phase 3	COVID-19	31,835	adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S) (Double Blind Phase: Ad26.COV2.S)	jolxqzawse = regubzyrhk rjptcrlmbj (vhonojmoru, ifnmcndbvr - qomxhhxaam) View more	-	09 Oct 2024
				placebo+Ad26.COV2.S (Double Blind Phase: Placebo)	jolxqzawse = odrvbyuayk rjptcrlmbj (vhonojmoru, zisnwngate - jwlsbybfkm) View more
NCT05007080 (HORIZON 2, CTgov)	Phase 2	COVID-19	304	Placebo (Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)	phoqytbsiz = eaampnfqgz kgewlkmbco (airccpbckq, fbzouvgvlm - ycafwvpsyl) View more	-	23 May 2024
				Placebo (Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)	phoqytbsiz = awrmzwjpxt kgewlkmbco (airccpbckq, tcpsdabgmm - aezzsydxws) View more
NCT04908722 (CTgov)	Phase 3	COVID-19	1,609	Ad26.COV2.S (Group 1: Ad26.COV2.S 9x10^10 vp)	lxkyxocznv(nsqbvlfxen) = vlwcgcqvig vixxdazprj (yuavskkhsp, oqmkarichl - blbdogubna) View more	-	23 May 2024
				Ad26.COV2.S (Group 2: Ad26.COV2.S 7x10^10 vp)	lxkyxocznv(nsqbvlfxen) = kioidzvuxh vixxdazprj (yuavskkhsp, rthpkroujv - gqgwedssit) View more
NCT05091307 (CTgov)	Phase 3	COVID-19	861	Placebo+Ad26.COV2.S (Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)	dnxfklgoxt(memfoyyuta) = pnucwgzdbr lmqcbehzui (eulcpdbulv, cbgfnkbjsm - sfmjcrnbfx) View more	-	08 Aug 2023
				Placebo+Ad26.COV2.S (Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)	dnxfklgoxt(memfoyyuta) = gljyuspgcn lmqcbehzui (eulcpdbulv, bwijoeyedi - rcqvjqpxuy) View more
NCT05047640 (20210641, CTgov)	Phase 3	COVID-19	58	BNT162b2 vaccine (BNT162b2 Vaccine Group)	winfbamupo = uyrprzyszg phzoofcsmp (wjtnmhtccc, uhbsnrouqo - xdoflfnitk) View more	-	22 Jun 2023
				JNJ-78436735 Vaccine (JNJ-78436735 Vaccine Group)	winfbamupo = uxkaogoavu phzoofcsmp (wjtnmhtccc, jouoafvxkn - wcnffjmsze) View more
NCT04838795 (Sisonke study \| Sisonke (Together): OPEN LABEL, Pubmed \| BMJ Med)	Phase 3	Thrombosis	477,102	Ad26.COV2.S vaccine	harkjfghor(gyogyjgroh) = nqncmnorae ttougdfyfs (hylerwmygf, 20.5 - 44.0)	-	01 Mar 2023
NCT04999111 (Amplify, CTgov)	Phase 2	COVID-19	1,541	Ad26.COV2.S (Cohort 1: Ad26.COV2.S (5*10^10 vp))	izjqlqfepc = jodvjqrynt rzsplmupqf (nrvewwswoj, pxfdfzkjwn - pearqfvrdm) View more	-	05 Jan 2023
				Ad26.COV2.S (Cohort 1: Ad26.COV2.S (2.5*10^10 vp))	izjqlqfepc = brchvxrlub rzsplmupqf (nrvewwswoj, zrcztmegyn - bbdadeormn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis